Freeman Patricia R, Walley Alexander Y, Winhusen T John, Oga Emmanuel A, Villani Jennifer, Hunt Timothy, Chandler Redonna K, Oyler Douglas R, Reilly Brittni, Gelberg Kitty, Douglas Christian, Lyons Michael S, Holloway JaNae, Vandergrift Nathan A, Adams Joella W, Asman Katherine, Baker Trevor J, Brancato Candace J, Cheng Debbie M, Childerhose Janet E, David James L, Feaster Daniel J, Gilbert Louisa, Glasgow LaShawn M, Goddard-Eckrich Dawn A, Knott Charles, Knudsen Hannah K, Lofwall Michelle R, Marks Katherine R, McMullan Jason T, Oser Carrie B, Roberts Monica F, Shoben Abigail B, Stein Michael D, Walters Scott T, Watson Josie, Zarkin Gary A, Jackson Rebecca D, Samet Jeffrey H, Walsh Sharon L, Bassel Nabila El
Patricia R. Freeman and Douglas R. Oyler are with the University of Kentucky College of Pharmacy, Department of Pharmacy Practice and Science, Lexington. Alexander Y. Walley, Trevor J. Baker, and Jeffrey H. Samet are with the Boston Medical Center, Boston, MA. T. John Winhusen is with the University of Cincinnati Department of Psychiatry and Behavioral Neuroscience, Cincinnati, OH. Emmanuel A. Oga, Christian Douglas, JaNae Holloway, Nathan A. Vandergrift, Joella W. Adams, Katherine Asman, LaShawn M. Glasgow, Charles Knott, and Gary A. Zarkin are with RTI International, Research Triangle Park, NC. Jennifer Villani and Redonna K. Chandler are with the National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. Timothy Hunt, Kitty Gelberg, James L. David, Louisa Gilbert, Dawn A. Goddard-Eckrich, and Nabila El Bassel are with the Columbia University School of Social Work, Social Intervention Group, New York, NY. Brittni Reilly is with the Massachusetts Department of Public Health, Boston. Michael S. Lyons is with Ohio State University Department of Emergency Medicine, Columbus. Candace J. Brancato is with the University of Kentucky College of Public Health, Department of Biostatistics, Lexington. Debbie M. Cheng is with the Boston University School of Public Health, Department of Biostatistics, Boston, MA. Janet E. Childerhose is and Rebecca D. Jackson was with the Ohio State University College of Medicine, Department of Internal Medicine, Columbus. Daniel J. Feaster is with the University of Miami Miller School of Medicine, Department of Public Health Sciences, Miami, FL. Hannah K. Knudsen, Michelle R. Lofwall, Katherine R. Marks, and Sharon L. Walsh are with the University of Kentucky College of Medicine, Department of Behavioral Science, Lexington. Jason T. McMullan is with the University of Cincinnati Department of Emergency Medicine, Cincinnati, OH. Carrie B. Oser is with the University of Kentucky, Department of Sociology, Lexington. Monica Roberts and Josie Watson are with the University of Kentucky Substance Use Priority Research Area, Lexington. Abigail B. Shoben is with the Ohio State University College of Public Health, Division of Biostatistics, Columbus. Michael D. Stein is with the Boston University School of Public Health, Department of Health Law, Policy, and Management, Boston, MA. Scott T. Walters is with the University of North Texas Health Science Center, School of Public Health, Fort Worth.
Am J Public Health. 2025 Jan;115(1):83-94. doi: 10.2105/AJPH.2024.307845. Epub 2024 Oct 10.
To determine whether the Communities That HEAL (CTH) intervention is effective in increasing naloxone distribution compared with usual care. The HEALing (Helping to End Addiction Long-Term) Communities Study (HCS) is a cluster-randomized, parallel-arm, wait-list controlled implementation science trial testing the impact of the CTH intervention on increasing the use of evidence-based practices to lower opioid-related overdose deaths. Communities (n = 67) highly impacted by opioid overdose in Kentucky, Massachusetts, New York, and Ohio were allocated to CTH intervention (n = 34) or wait-list comparison (usual care; n = 33) arms. The primary outcome for this study was the number of naloxone units distributed in HCS communities during the comparison period (July 1, 2021‒June 30, 2022), examined using an intent-to-treat negative binomial regression model. Naloxone distribution was 79% higher in the CTH intervention versus usual care arm (adjusted relative rate = 1.79; 95% confidence interval = 1.28, 2.51; = .001; adjusted rates of naloxone distribution 3378 vs 1884 naloxone units per 100 000 residents), when controlling for urban‒rural status, state, baseline opioid-related overdose death rate, and baseline naloxone distribution rate. The CTH intervention increased naloxone distribution compared with usual care in communities highly impacted by the opioid crisis. ClinicalTrials.gov identifier: NCT04111939. (. 2025;115(1):83-94. https://doi.org/10.2105/AJPH.2024.307845).
为确定“治愈社区(CTH)”干预措施与常规护理相比,在增加纳洛酮分发方面是否有效。“治愈(长期帮助戒除成瘾)社区研究(HCS)”是一项整群随机、平行组、等待列表对照的实施科学试验,旨在测试CTH干预措施对增加循证实践的使用以降低阿片类药物相关过量死亡的影响。在肯塔基州、马萨诸塞州、纽约州和俄亥俄州受阿片类药物过量影响严重的社区(n = 67)被分配到CTH干预组(n = 34)或等待列表对照组(常规护理;n = 33)。本研究的主要结局是在比较期(2021年7月1日至2022年6月30日)HCS社区分发的纳洛酮单位数量,使用意向性分析负二项回归模型进行检验。在控制城乡状况、州、基线阿片类药物相关过量死亡率和基线纳洛酮分发率后,CTH干预组的纳洛酮分发量比常规护理组高79%(调整相对率 = 1.79;95%置信区间 = 1.28,2.51;P = 0.001;纳洛酮分发调整率为每10万居民3378单位对1884单位)。与常规护理相比,CTH干预措施增加了受阿片类药物危机严重影响社区的纳洛酮分发量。临床试验.gov标识符:NCT04111939。(. 2025;115(1):83 - 94. https://doi.org/10.2105/AJPH.2024.307845)